Authors’ Disclosure Statement: Dr. Erickson reports that he is a Committee Member for the American Orthopaedic Society for Sports Medicine (AOSSM). Dr. Cole reports that he submitted on 07/18/2018; Aesculap/B.Braun, research support; American Journal of Orthopedics, editorial or governing board; American Journal of Sports Medicine, editorial or governing board; Aqua Boom, stock or stock options; Arthrex, Inc, intellectual property (IP) royalties, paid consultant, research support; Arthroscopy, editorial or governing board; Arthroscopy Association of North America, board or committee member; Athletico, other financial or material support; Biomerix, stock or stock options; Cartilage, editorial or governing board; DJ Orthopaedics, IP royalties; Elsevier Publishing, IP royalties; Flexion, paid consultant; Geistlich, research support; Giteliscope, stock or stock options; International Cartilage Repair Society, board or committee member; Journal of Bone and Joint Surgery – American, editor only, editorial or governing board; Journal of Shoulder and Elbow Surgery, editor only, editorial or governing board; Journal of the American Academy of Orthopaedic Surgeons, editor only, editorial or governing board; JRF Ortho, other financial or material support; National Institutes of Health (NIAMS and NICHD), research support; Operative Techniques in Sports Medicine, publishing royalties, financial or material support; Ossio, stock or stock options; Regentis, paid consultant, stock or stock options; Sanofi-Aventis, research support; Smith & Nephew, other financial or material support, paid consultant; Tornier, other financial or material support; and Zimmer Biomet, paid consultant, research support. Dr. Verma reports that he is AOSSM, board or committee member; American Shoulder and Elbow Surgeons, board or committee member; Arthrex, Inc, paid consultant, research support; Arthroscopy, editorial or governing board, publishing royalties, financial or material support; Arthroscopy Association of North America, board or committee member; Arthrosurface, research support; Cymedica, stock or stock options; DJ Orthopaedics, research support; Journal of Knee Surgery, editorial or governing board; Minivasive, paid consultant, stock or stock options; Omeros, stock or stock options; Orthospace, paid consultant; Össur, research support; SLACK Incorporated, editorial or governing board; Smith & Nephew, IP royalties; Smith & Nephew, Athletico, ConMed Linvatec, Miomed, and Mitek, research support; and Vindico Medical-Orthopedics Hyperguide, publishing royalties, financial or material support. Dr. Nicholson reports that he is American Shoulder and Elbow Surgeons, board or committee member; Arthrosurface, paid presenter or speaker; Innomed, IP royalties; Tornier, paid consultant; and Wright Medical Technology, Inc., IP royalties, paid consultant. Dr. Romeo reports that he is American Association of Nurse Anesthetists, other financial or material support; Aesculap/B.Braun, research support; American Shoulder and Elbow Surgeons, board or committee member; Arthrex, Inc, IP royalties, other financial or material support, paid consultant, paid presenter or speaker, research support; Atreon Orthopaedics, board or committee member; Histogenics, research support; Medipost, research support; Major League Baseball, other financial or material support; NuTech, research support; Orthopedics, editorial or governing board; Orthopedics Today, board or committee member, editorial or governing board; OrthoSpace, research support; SAGE, editorial or governing board; Saunders/Mosby-Elsevier, publishing royalties, financial or material support; SLACK Incorporated, editorial or governing board, publishing royalties, financial or material support; Smith & Nephew, research support; Wolters Kluwer Health-Lippincott Williams & Wilkins, editorial or governing board; and Zimmer Biomet, research support. Dr. Harris reports that he is American Academy of Orthopaedic Surgeons, board or committee member; TheAmerican Journal of Orthopedics, editorial or governing board; AOSSM, board or committee member; Arthroscopy, editorial or governing board; Arthroscopy Association of North America, board or committee member; DePuy Synthes, A Johnson & Johnson Company, research support; Frontiers In Surgery, editorial or governing board; NIA Magellan, paid consultant; Össur, paid consultant, paid presenter or speaker; SLACK Incorporated, publishing royalties, financial or material support; and Smith & Nephew, paid consultant, paid presenter or speaker, research support. Dr. Bohl reports no actual or potential conflict of interest in relation to this article.
Dr. Erickson is an Attending Surgeon, Sports Medicine and Shoulder Division, Rothman Orthopadic Institute, New York, New York. He was a resident at the time the article was written. Dr. Bohl is an Orthopaedic Surgery Resident, Rush University; Dr. Cole, Dr. Verma, and Dr. Nicholson are Orthopaedic Surgery Attendings, Sports Medicine and Shoulder and Elbow and Sports Division, Midwest Orthopaedics, Rush University Medical Center, Chicago, Illinois. Dr. Romeo is the Managing Partner, Division Chief Shoulder & Elbow and Sports Medicine Department, and Attending Surgeon at Rothman Orthopadics Institute, New York, New York. Dr. Harris is an Orthopaedic Surgery Attending, Sports Medicine Department, Houston Methodist Hospital, Houston, Texas.
Address correspondence to: Brandon J. Erickson, MD, Rothman Orthopaedic Institute, 658 White Plains Road, Tarrytown, NY, 10591 (tel, 800-321-9999; email, brandon.j.erickson@gmail.com).
Brandon J. Erickson, MD Daniel D. Bohl, MD, MPH Brian J. Cole, MBA, MD Nikhil N. Verma, MD Gregory Nicholson, MD Anthony A. Romeo, MD and Joshua D. Harris, MD . Reverse Total Shoulder Arthroplasty: Indications and Techniques Across the World. Am J Orthop.
September 26, 2018
References
RESULTS
There were 103 studies included in the analysis (Figure 1). A total of 8973 patients were included, 62% of whom were female with a mean age of 70.9 ± 6.7 years (Table 1). The average follow-up was 34.3 ± 19.3 months. North America had the overall greatest total number of publications on RTSA, followed by Europe (Figure 2). The total yearly number of publications increased by a mean of 1.95 publications each year (P < .001). There was no association between the mean level of evidence with the year of publication (P = .296) (Figure 3). Overall, the rating of studies was poor for the MCMS (mean 36.9 ± 8.7). The MCMS decreased each year by a mean of 0.76 points (P = .037) (Figure 4).
Table 1. Demographic Data by Continent
North America
Europe
Asia
Australia
Total
P-value
Number of studies
52
43
4
4
103
-
Number of subjects
6158
2609
51
155
8973
-
Level of evidence
0.693
II
5 (10%)
3 (7%)
0 (0%)
0 (0%)
8 (8%)
III
10 (19%)
4 (9%)
0 (0%)
1 (25%)
15 (15%)
IV
37 (71%)
36 (84%)
4 (100%)
3 (75%)
80 (78%)
Mean MCMS
34.6 ± 8.4
40.2 ± 8.0
32.5 12.4
34.5 ± 6.6
36.9 ± 8.7
0.010
Institutional collaboration
1.000
Multi-center
7 (14%)
6 (14%)
0 (0%)
0 (0%)
13 (13%)
Single-center
45 (86%)
37 (86%)
4 (100%)
4 (100%)
90 (87%)
Financial conflict of interest
0.005
Present
28 (54%)
15 (35%)
0 (0%)
0 (0%)
43 (42%)
Not present
19 (37%)
16 (37%)
4 (100%)
4 (100%)
43 (42%)
Not reported
5 (10%)
12 (28%)
0 (0%)
0 (0%)
17 (17%)
Sex
N/A
Male
2157 (38%)
1026 (39%)
13 (25%)
61 (39%)
3257 (38%)
Female
3520 (62%)
1622 (61%)
38 (75%)
94 (61%)
5274 (62%)
Mean age (years)
71.3 ± 5.6
70.1 ± 7.9
68.1 ± 5.3
76.9 ± 3.0
70.9 ± 6.7
0.191
Minimum age (mean across studies)
56.9 ± 12.8
52.8 ± 15.7
62.8 ± 6.2
68.0 ± 12.1
55.6 ± 14.3
0.160
Maximum age (mean across studies)
82.1 ± 8.6
83.0 ± 5.5
73.0 ± 9.4
85.0 ± 7.9
82.2 ± 7.6
0.079
Mean length of follow-up (months)
26.5 ± 13.7
43.1 ± 21.7
29.4 ± 7.9
34.2 ± 16.6
34.3 ± 19.3
<0.001
Prosthesis type
N/A
Cemented
988 (89%)
969 (72%)
0 (0%)
8 (16%)
1965 (78%)
Press fit
120 (11%)
379 (28%)
0 (0%)
41 (84%)
540 (22%)
Abbreviations: MCMS, Modified Coleman Methodology Score; N/A, not available.
In studies that reported press-fit vs cemented prostheses, the highest percentage of press-fit prostheses compared with cemented prostheses was seen in Australia (84% press-fit), whereas the highest percentage of cemented prostheses was seen in North America (89% cemented). A higher percentage of studies from North America had a financial conflict of interest (COI) than did those from other countries (54% had a COI).